RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Revenue growth (%)

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndRevenue growth (%) YoY (%)
Dec 31, 20248.3+6.57%
Dec 31, 20237.8-131.99%
Dec 31, 2022-24.3-127.22%
Dec 31, 202189.1+1005.96%
Dec 31, 20208.1-53.08%
Dec 31, 201917.2+20.31%
Dec 31, 201814.3-31.41%
Dec 31, 201720.8+12.91%
Dec 31, 201618.4-59.52%
Dec 31, 201545.6+34.13%
Dec 31, 201434-35.55%
Dec 31, 201352.7-74.81%
Dec 31, 2012209.2-7338.75%
Dec 31, 2011-2.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)